Lacerta Bio is a business development consultancy specializing in identifying, assessing, negotiating, and closing licensing and partnership opportunities for the pharmaceutical, biotechnology, and drug delivery industries.
We also work with and support internal business development teams with market research, competitive intelligence, financial modeling, and other support services.
In November, 2014, we announced a merger with Copenhagen-based Ventac Partners. The combination of Lacerta Bio and Ventac Partners will dramatically increase the types of services we can offer our clients, as well as expand our geographic reach.
If you need assistance finding or assessing business development and/or partnership opportunities, contact us at email@example.com.
Lacerta Bio is seeking parenteral products for in-licensing on behalf of a US-based client. Key criteria are: Products which can be developed via the 505(b)(2) regulatory process in the US No specific therapeutic area Injectable could be infusion, prefilled syringe, or related presentation Products already approved outside the US are especially welcome Delivery / formulationRead More»
Lacerta Bio is looking to transact a business acquisition opportunity in the injectables manufacturing sector. We are seeking manufacturing facilities which have the following criteria: Based outside the US (Europe, Canada, LatAm, Australia, New Zealand preferred) FDA or EU approved manufacturing of parenteral products Could be a stand-alone company which manufactures its own products, or the divestmentRead More»
Would You Like To Expand Your Business Into China? Or Perhaps You Seek An Investor or Development Partner? China is a large and growing opportunity for Western life science companies, as: Life Science in China is Booming – China’s life science industry has been growing at more than 20%+ per year, and is expect toRead More»
Ample numbers of electrons will be spent discussing the BIO2016 conference in San Francisco last week, both positive and negative.
Not wanting to be left out of the fun, here are a few of our observations, with the usual caveats about not attending company presentations, etc.
Ten Thousand Steps – We averaged 10,274 steps from June 5 through June 10. During the course of these many steps, we obviously heard many complaints about the distances between meetings. Rather than complain about it, it’s interesting to think back to previous BIO conventions.
Which cities have the convention center, hotels, and other accoutrements necessary to host this massive event? Certainly previous conventions in Philadelphia, Chicago, Boston, and San Diego worked quite well.
This idea of multi-building conferences is not unique to BIO, as the organizers of the most recent Biotech Showcase learned.
But was it really that bad? Generally speaking, it was not. In fact, hosted a record-breaking 37,500 partnering meetings. However, a few exhibitors we spoke with made comments about reduced foot traffic compared to prior BIO conferences. Whether this will make much of a difference in the long run is an open question.
We will be returning to San Diego next year, follow by returns to Boston in 2018 and Philadelphia in 2019. Future convention dates are listed here. So we can all relax. Our step counts for the next three conventions will be lower (maybe).
It’s All Personal – Whoever conceived the idea that business is not personal did not know what s/he was talking about. As a consultant, there is no question that we do what is in the best financial and corporate interests of our clients. But we cannot ignore the personal side of our activities.
We are convinced that there are folks in our community who use “business” to treat people in ways which would not be acceptable in any other environment. Yet this is a huge mistake, especially in our highly connected, increasingly social business environment. For a few good articles on this idea, check out this one, this one, and especially this one.
Partnering – What about the partnering discussions in the partnering booths? Looking through our meeting list, we noticed a few themes:
Late-stage antibiotics remain an enigma. On the one hand, resistance patterns point towards clear unmet medical needs. Yet these markets are primarily low prevalence/high cost, which are not exactly what payers want to see.
Further, resistance patterns can differ from geography to geography, perhaps limiting the global licensing opportunity for a company developing novel antibiotics.
Drug delivery and reformulation remains a highly viable approach to develop products which provide relevant clinical benefits. But licensing these kinds of products prior to Phase III remain a challenge.
Thus, the challenge for management teams is to convince investors that the funds required will either generate a license with highly favorable ROI for investors, or that taking the product all the way to commercialization will provide an even higher ROI.
Animal Health licensing remains very strong. Major animal health companies remain highly interested in novel therapeutics for both food and companion animals. Innovators will likely have to collaborate with the animal health companies to build strong business cases to sell opportunities internally.
What’s Next? – For us, the net few weeks are busy with follow up phone calls, emails, term sheets, and proposals. It’s critical to complete this activity before the July-August vacation season slow down. The next conference for us will be BIO-Europe Fall in Cologne in November. See you there!
Next week, our industry makes an unusual return trip to Union Square, as we return for another conference. This time, it’s BIO. BIO is unlike other conferences on our circuit, for a few reasons: Size – BIO isn’t just big. It’s massive. Consider, for example, that there are over 6,000 delegates registered for One-on-One partnering.
There is an interesting article in the current issue of The Journal of Precision Medicine on Alzheimer’s. The article attempts to answer a seemingly simple, yet complex question…Can systems biology and precision medicine approaches be used to understand the disease better and develop more effective therapies? First, a few of our highlights from the article:
Our friends at PharmaCircle recently published an interesting and provocative piece entitled Injectables: The New Oral? The PDF is available here. The article notes that, in 2014, seven of the top ten pharmaceuticals were parenteral products, with products such as Humira, Remicade, and Enbrel achieving $9-12+ billion in sales. This is a huge change from